Details of the Drug Combination

General Information of Drug Combination (ID: DCSWFI2)

• Drug Combination Name: Gentamicin + Benzylpenicillin
• Indication: Malnutrition Severe; Status: Phase 3 [1]
• Component Drugs:
  Gentamicin (DMKINJO): Small molecular drug
  Benzylpenicillin (DMS9503): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Gentamicin

Disease Entry	ICD 11	Status	REF
Bacteremia	1A73	Approved	[2]
Bacterial infection	1A00-1C4Z	Approved	[3]
Blepharoconjunctivitis	N.A.	Approved	[2]
Cholangitis	N.A.	Approved	[2]
Dacryocystitis	N.A.	Approved	[2]
Demodex blepharitis	1G07	Approved	[2]
Folliculitis	N.A.	Approved	[2]
Neonatal sepsis	N.A.	Approved	[2]
Paronychia	1F23.13	Approved	[2]
Peritonitis	N.A.	Approved	[2]
Pseudomonas aeruginosa infectious disease	N.A.	Approved	[2]

Gentamicin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Bacterial 30S ribosomal RNA (Bact 30S rRNA)	TTOVFH2	NOUNIPROTAC	Modulator	[44]

Gentamicin Interacts with 6 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Aminoglycoside O-phosphotransferase (aphA6)	DEWPAJD	KKA6_ACIBA	Metabolism	[45]
Aminoglycoside phosphotransferase (aph-Ib)	DE5WGIM	A0A075C7U3_CAMJU	Metabolism	[46]
Kanamycin/gentamycin-resistance enzyme (aacA)	DECXWN8	J3S7E2_CAMCO	Metabolism	[46]
Endoglucanase Y (EGY)	DE2M583	A0A256VAC0_LACRE	Metabolism	[47]
Endoglucanase Y (EGY)	DE2AZTG	A0A256VAC0_LACRE	Metabolism	[47]
Aminoglycoside 6'-N-acetyltransferase (aacA)	DE48UAX	C5MQW3_KLEPO	Metabolism	[48]

Gentamicin Interacts with 53 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Alpha-L-iduronidase (IDUA)	OTTQQ7FN	IDUA_HUMAN	Increases Expression	[49]
Tripeptidyl-peptidase 1 (TPP1)	OT2LQ771	TPP1_HUMAN	Increases Expression	[50]
Exocyst complex component 3 (EXOC3)	OT8N3306	EXOC3_HUMAN	Increases Expression	[51]
Slit homolog 1 protein (SLIT1)	OT35RBNT	SLIT1_HUMAN	Decreases Expression	[43]
Coagulation factor VIII (F8)	OTH6XHDU	FA8_HUMAN	Increases Expression	[52]
Coagulation factor IX (F9)	OTT0CX3Q	FA9_HUMAN	Increases Expression	[52]
Cystatin-C (CST3)	OTNZ6AO4	CYTC_HUMAN	Increases Expression	[51]
Pro-epidermal growth factor (EGF)	OTANRJ0L	EGF_HUMAN	Decreases Expression	[51]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Decreases Expression	[53]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[51]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Increases Expression	[51]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[42]
Heat shock 70 kDa protein 1A (HSPA1A)	OTKGIE76	HS71A_HUMAN	Increases Expression	[54]
Dystrophin (DMD)	OTD21T5J	DMD_HUMAN	Increases Expression	[55]
Xaa-Pro dipeptidase (PEPD)	OT3LFY7S	PEPD_HUMAN	Decreases Activity	[56]
Cystic fibrosis transmembrane conductance regulator (CFTR)	OT6B22QH	CFTR_HUMAN	Increases Activity	[57]
Aminopeptidase N (ANPEP)	OTP3WYFD	AMPN_HUMAN	Increases Secretion	[58]
Methylmalonyl-CoA mutase, mitochondrial (MMUT)	OTBBBV70	MUTA_HUMAN	Affects Expression	[59]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[42]
Endothelin receptor type B (EDNRB)	OTLLZV3P	EDNRB_HUMAN	Increases Expression	[43]
Insulin-like growth factor-binding protein 5 (IGFBP5)	OTRE5V0C	IBP5_HUMAN	Decreases Expression	[43]
HLA class I histocompatibility antigen, alpha chain F (HLA-F)	OT76CM19	HLAF_HUMAN	Increases Expression	[43]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Expression	[51]
Leukemia inhibitory factor receptor (LIFR)	OT36W9O5	LIFR_HUMAN	Decreases Degradation	[60]
ATP-sensitive inward rectifier potassium channel 1 (KCNJ1)	OTIXCRI6	KCNJ1_HUMAN	Increases Expression	[61]
Cytosolic purine 5'-nucleotidase (NT5C2)	OTJMF66Z	5NTC_HUMAN	Increases Expression	[43]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Expression	[51]
Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4)	OT29B58J	KCNQ4_HUMAN	Decreases Expression	[43]
Beta-2-microglobulin (B2M)	OTDWN6NX	B2MG_HUMAN	Increases Expression	[62]
Neutrophil gelatinase-associated lipocalin (LCN2)	OTSB42BR	NGAL_HUMAN	Decreases Secretion	[63]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[51]
Serine-protein kinase ATM (ATM)	OTQVOHLT	ATM_HUMAN	Increases Expression	[64]
Polycystin-2 (PKD2)	OTIXBU8H	PKD2_HUMAN	Increases Expression	[65]
Runt-related transcription factor 3 (RUNX3)	OTITK1XD	RUNX3_HUMAN	Decreases Expression	[43]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	OTXEE550	APR_HUMAN	Increases Expression	[42]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Decreases Expression	[51]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Expression	[51]
Partitioning defective 3 homolog (PARD3)	OTH5BPLO	PARD3_HUMAN	Decreases Expression	[43]
GATOR1 complex protein NPRL2 (NPRL2)	OTOB10MO	NPRL2_HUMAN	Decreases Expression	[43]
Hepatitis A virus cellular receptor 1 (HAVCR1)	OT184CRZ	HAVR1_HUMAN	Increases Expression	[51]
Rho guanine nucleotide exchange factor 26 (ARHGEF26)	OTX0U8PX	ARHGQ_HUMAN	Increases Expression	[43]
G-protein coupled receptor 20 (GPR20)	OTPCR8F7	GPR20_HUMAN	Increases Expression	[43]
Polyadenylate-binding protein-interacting protein 1 (PAIP1)	OTL2F5T5	PAIP1_HUMAN	Decreases Expression	[43]
Large subunit GTPase 1 homolog (LSG1)	OTDAXJ9L	LSG1_HUMAN	Decreases Expression	[43]
Glyoxalase domain-containing protein 4 (GLOD4)	OTBJKFXA	GLOD4_HUMAN	Decreases Expression	[43]
DNA-directed DNA/RNA polymerase mu (POLM)	OT0SRIP4	DPOLM_HUMAN	Increases Expression	[43]
Ubiquitin-like-conjugating enzyme ATG3 (ATG3)	OT28VBVK	ATG3_HUMAN	Decreases Expression	[43]
Phospholipase A2 (PLA2G1B)	OT1GG9FK	PA21B_HUMAN	Increases ADR	[66]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1)	OT9HYT7A	PLCB1_HUMAN	Increases ADR	[66]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1)	OTCJ458Q	AT1A1_HUMAN	Increases ADR	[66]
Solute carrier family 22 member 2 (SLC22A2)	OTGFK1AL	S22A2_HUMAN	Increases Transport	[67]
Lysosomal Pro-X carboxypeptidase (PRCP)	OTIUY91L	PCP_HUMAN	Increases ADR	[66]
Dipeptidyl aminopeptidase-like protein 6 (DPP6)	OTWW3H0K	DPP6_HUMAN	Increases ADR	[66]

Indication(s) of Benzylpenicillin

Disease Entry	ICD 11	Status	REF
Actinomycosis	N.A.	Approved	[4]
Acute otitis media	AB00	Approved	[5]
Anthrax	1B97	Approved	[6]
Bacterial endocarditis	N.A.	Approved	[7]
Botulism	1A11	Approved	[8]
Cervicofacial actinomycosis	N.A.	Approved	[9]
Congenital syphilis	N.A.	Approved	[10]
Cutaneous anthrax	N.A.	Approved	[11]
Erysipelas	N.A.	Approved	[12]
Erysipelothrix rhusiopathiae infectious disease	N.A.	Approved	[13]
Gastrointestinal anthrax	N.A.	Approved	[14]
Gonococcal infection of joint	N.A.	Approved	[15]
Inhalational anthrax	N.A.	Approved	[6]
Late latent syphilis	N.A.	Approved	[16]
Latent syphilis	N.A.	Approved	[17]
Latent yaws	N.A.	Approved	[18]
Listeria meningitis	N.A.	Approved	[19]
Lung abscess	N.A.	Approved	[20]
Meningococcal meningitis	N.A.	Approved	[21]
Meningococcemia	N.A.	Approved	[22]
Neonatal sepsis	N.A.	Approved	[23]
Neurosyphilis	N.A.	Approved	[24]
Pasteurella multocida infectious disease	N.A.	Approved	[25]
Pasteurellosis	N.A.	Approved	[26]
Pneumococcal meningitis	N.A.	Approved	[19]
Psoriasis	EA90	Approved	[27]
Rat-bite fever	N.A.	Approved	[28]
Respiratory tract infection	CA45	Approved	[29]
Staphylococcus aureus infection	N.A.	Approved	[30]
Streptococcal pneumonia	N.A.	Approved	[31]
Streptococcal toxic-shock syndrome	N.A.	Approved	[32]
Streptococcus infection	1B53	Approved	[33]
Syphilis	N.A.	Approved	[34]
Tertiary lesion of yaws	N.A.	Approved	[35]
Yaws	N.A.	Approved	[36]
Bejel	N.A.	Investigative	[37]
Latent early syphilis	N.A.	Investigative	[38]
Secondary syphilis	N.A.	Investigative	[39]
Tertiary syphilis	N.A.	Investigative	[40]
Tetanus	1C13	Investigative	[41]

Benzylpenicillin Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Bacterial Penicillin binding protein 3 (Bact mrcA)	TT85JMW	FTSI_ECOLI	Binder	[69]
Bacterial Penicillin binding protein 1 (Bact pbp)	TTTKCMH	PBPA_ECOLI; PBPB_ECOLI; PBPC_ECOLI	Binder	[70]

Benzylpenicillin Interacts with 7 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[71]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[72]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[73]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[74]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[75]
Organic anion transporting polypeptide 3A1 (SLCO3A1)	DTVNRXW	SO3A1_HUMAN	Substrate	[75]
Organic anion transporting polypeptide 4A1 (SLCO4A1)	DT8H2IC	SO4A1_HUMAN	Substrate	[75]

Benzylpenicillin Interacts with 11 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Beta-lactamase (blaB)	DEV0KWQ	Q8KT52_9BACT	Metabolism	[76]
N-acylhomoserine lactone acylase (lacA)	DEIU0XN	A0A0A1VBK6_9BURK	Metabolism	[77]
Beta-lactamase (blaB)	DET9I1W	BLAC_BACUN	Metabolism	[78]
Beta-lactamase (blaB)	DENJ2SQ	BLAB_BACFG	Metabolism	[76]
Beta-lactamase (blaB)	DESIWFO	Q8GQK7_9FLAO	Metabolism	[79]
Beta-lactamase (blaB)	DEQX0DG	Q8RIK5_FUSNN	Metabolism	[80]
Beta-lactamase (blaB)	DE37FJH	C6JIU1_FUSVA	Metabolism	[76]
Beta-lactamase (blaB)	DEAILCM	A0A246EJV2_9BACT	Metabolism	[81]
Beta-lactamase (blaB)	DERPJ4F	A0A2S8IKB0_BURCE	Metabolism	[82]
Beta-lactamase (blaB)	DEBAZ7H	F9DGI4_9BACT	Metabolism	[81]
Beta-lactamase (blaB)	DEA5OYT	A0A4U8WDG3_9FLAO	Metabolism	[83]

Benzylpenicillin Interacts with 19 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Organic anion transporter 3 (SLC22A8)	OT8BY933	S22A8_HUMAN	Increases Uptake	[84]
Pirin (PIR)	OT8ALXHU	PIR_HUMAN	Increases Expression	[85]
Tripartite motif-containing protein 16 (TRIM16)	OTLRXYOZ	TRI16_HUMAN	Increases Expression	[85]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases Expression	[85]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[85]
Liver carboxylesterase 1 (CES1)	OT9L0LR8	EST1_HUMAN	Increases Expression	[85]
Glutamate--cysteine ligase regulatory subunit (GCLM)	OT6CP234	GSH0_HUMAN	Increases Expression	[85]
Insulin-like growth factor II (IGF2)	OTJ4O6MW	IGF2_HUMAN	Decreases Expression	[68]
Alpha-fetoprotein (AFP)	OT9GG3ZI	FETA_HUMAN	Decreases Expression	[68]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Decreases Expression	[68]
Decorin (DCN)	OTWLJL7K	PGS2_HUMAN	Decreases Expression	[68]
Annexin A8 (ANXA8)	OTLSSQCY	ANXA8_HUMAN	Decreases Expression	[68]
Insulin-like growth factor-binding protein 5 (IGFBP5)	OTRE5V0C	IBP5_HUMAN	Decreases Expression	[68]
Secreted frizzled-related protein 3 (FRZB)	OTTO3DPY	SFRP3_HUMAN	Decreases Expression	[68]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[86]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[86]
T-lymphocyte activation antigen CD86 (CD86)	OTJCSBPC	CD86_HUMAN	Increases Expression	[87]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Increases Expression	[88]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Increases Transport	[89]

References

• [1] ClinicalTrials.gov (NCT03174236) First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition
• [2] Gentamicin FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2427).
• [4] Abdominal actinomycosis after reparative surgery for cholecystogastric fistula in an immunosuppressed patient. BMJ Case Rep. 2021 Jul 23;14(7):e243445.
• [5] Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children with acute otitis media in Japan from 2014 to 2017. J Infect Chemother. 2019 Mar;25(3):229-232.
• [6] Human Anthrax: Update of the Diagnosis and Treatment. Diagnostics (Basel). 2023 Mar 10;13(6):1056.
• [7] Optimisation of the prevention and treatment of bacterial endocarditis. Drugs Aging. 2001;18(6):415-24.
• [8] Clinical Serum Therapy: Benefits, Cautions, and Potential Applications. Keio J Med. 2017 Dec 25;66(4):57-64.
• [9] Cervicofacial actinomycosis: a report of 14 patients observed at the Dermatology Unit of the University of Milan, Italy. Int J Dermatol. 2020 Oct;59(10):1222-1225.
• [10] Congenital syphilis in a preterm newborn with gastrointestinal disorders and postnatal growth restriction. Ital J Pediatr. 2022 Dec 29;48(1):205.
• [11] Cutaneous Anthrax. J Emerg Med. 2017 Feb;52(2):240-241.
• [12] [Streptococcus pyogenes--much more than the aetiological agent of scarlet fever]. Med Monatsschr Pharm. 2009 Nov;32(11):408-16; quiz 417-8.
• [13] Erysipelothrix rhusiopathiae bloodstream infection - A 22-year experience at Mayo Clinic, Minnesota. Zoonoses Public Health. 2017 Nov;64(7):e65-e72.
• [14] Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases: 1900 to 2005. Arch Pediatr Adolesc Med. 2007 Sep;161(9):896-905.
• [15] Infectious arthritis. Infect Dis Clin North Am. 1990 Sep;4(3):523-38.
• [16] Syphilis. Lancet. 2023 Jul 22;402(10398):336-346.
• [17] Diagnosis, treatment, and notification of syphilis during pregnancy in the state of Gois, Brazil, between 2007 and 2017. Rev Saude Publica. 2021 Oct 29;55:68.
• [18] Yaws. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
• [19] Meningitis in adults: diagnosis and management. Intern Med J. 2018 Nov;48(11):1294-1307.
• [20] Spontaneous Clostridium perfringens lung abscess unresponsive to penicillin. Anaesth Intensive Care. 1993 Feb;21(1):117-9.
• [21] Meningococcal meningitis and diabetes insipidus. Scand J Infect Dis. 1988;20(3):341-3.
• [22] [An unusual cause of fever: chronic meningococcemia]. Ned Tijdschr Geneeskd. 1996 Apr 6;140(14):785-7.
• [23] Antibiotic regimens for early-onset neonatal sepsis. Cochrane Database Syst Rev. 2021 May 17;5(5):CD013837.
• [24] Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study. Lancet Infect Dis. 2021 Oct;21(10):1441-1447.
• [25] Pasteurella multocida pneumonia. Semin Respir Infect. 1997 Mar;12(1):54-6.
• [26] Pasteurella Multocida. 2023 May 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
• [27] A review of antibiotics and psoriasis: induction, exacerbation, and amelioration. Expert Rev Clin Pharmacol. 2019 Oct;12(10):981-989.
• [28] Rat-Bite Fever. 2023 Mar 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
• [29] Benzylpenicillin versus wide-spectrum beta-lactam antibiotics as empirical treatment of Haemophilus influenzae-associated lower respiratory tract infections in adults; a retrospective propensity score-matched study. Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1761-1775.
• [30] In vivo synergy between 6 beta-amidinopenicillanic acid derivatives and other antibiotics. Antimicrob Agents Chemother. 1976 Apr;9(4):589-94.
• [31] Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009 Oct 31;374(9700):1543-56.
• [32] [Beta-hemolytic streptococcal bacteremia in adults]. Duodecim. 2013;129(14):1477-84.
• [33] Prevalence and treatment of group B streptococcus colonization based on risk factors versus intrapartum culture screening. Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:178-181.
• [34] Diagnosis and treatment of syphilis in pregnant women at the services of Primary Care. Cien Saude Colet. 2022 Aug;27(8):3331-3340.
• [35] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [36] Yaws Osteoperiostitis Treated with Single-Dose Azithromycin. Am J Trop Med Hyg. 2017 May;96(5):1039-1041.
• [37] 2020 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):574-588.
• [38] Syphilis. Enferm Infecc Microbiol Clin (Engl Ed). 2019 Jun-Jul;37(6):398-404.
• [39] Secondary Syphilis. Clin Pract Cases Emerg Med. 2020 Nov;4(4):675-676.
• [40] A rare case of tertiary syphilis spondylodiscitis of the upper cervical spine: Diagnostic and therapeutic complexity, review of literature. Orthop Rev (Pavia). 2020 Jun 25;12(Suppl 1):8675.
• [41] Benzathine penicillin, metronidazole and benzyl penicillin in the treatment of tetanus: a randomized, controlled trial. Ann Trop Med Parasitol. 2004 Jan;98(1):59-63.
• [42] A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
• [43] Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
• [44] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [45] Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
• [46] Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
• [47] Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
• [48] Detection of multidrug-resistant Enterobacteriaceae isolated from river waters flowing to the Guanabara Bay and from clinical samples of hospitals in Rio de Janeiro, Brazil. Biomedica. 2019 May 1;39(s1):135-149.
• [49] Alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol. 2004 Apr 30;338(3):453-62.
• [50] Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol. 2001;5 Suppl A:57-62. doi: 10.1053/ejpn.2000.0436.
• [51] In vitro evaluation of biomarkers of nephrotoxicity through gene expression using gentamicin. J Biochem Mol Toxicol. 2018 Sep;32(9):e22189. doi: 10.1002/jbt.22189. Epub 2018 Jul 10.
• [52] Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood. 2005 Nov 1;106(9):3043-8. doi: 10.1182/blood-2005-03-1307. Epub 2005 Jul 28.
• [53] Gentamicin suppresses endotoxin-driven TNF-alpha production in human and mouse proximal tubule cells. Am J Physiol Renal Physiol. 2007 Oct;293(4):F1373-80. doi: 10.1152/ajprenal.00333.2007. Epub 2007 Aug 15.
• [54] Increased expression of heat shock protein (HSP)72 in a human proximal tubular cell line (HK-2) with gentamicin-induced injury. J Toxicol Sci. 2006 Feb;31(1):61-70. doi: 10.2131/jts.31.61.
• [55] Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 2003 May;22(1):15-21.
• [56] Melanin potentiates gentamicin-induced inhibition of collagen biosynthesis in human skin fibroblasts. Eur J Pharmacol. 2002 Jun 20;446(1-3):7-13. doi: 10.1016/s0014-2999(02)01793-4.
• [57] Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells. Hepatology. 2002 Jan;35(1):95-104. doi: 10.1053/jhep.2002.30423.
• [58] Investigations on the potential nephrotoxicity of cefazedone and gentamicin and of their combination, in comparison with the combination of cefazolin and cephalothin with gentamicin. Arzneimittelforschung. 1979;29(2a):449-52.
• [59] Stop codon read-through of a methylmalonic aciduria mutation. Mol Genet Metab. 2009 Aug;97(4):244-9. doi: 10.1016/j.ymgme.2009.04.004. Epub 2009 Apr 12.
• [60] In vitro readthrough of termination codons by gentamycin in the Stve-Wiedemann Syndrome. Eur J Hum Genet. 2010 Jan;18(1):130-2. doi: 10.1038/ejhg.2009.122.
• [61] Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 2003 Sep;64(3):923-32. doi: 10.1046/j.1523-1755.2003.00153.x.
• [62] The absence of nephrotoxicity and differential nephrotoxicity between tobramycin and gentamicin. South Med J. 1990 Oct;83(10):1149-52. doi: 10.1097/00007611-199010000-00008.
• [63] Neutrophil gelatinase-associated lipocalin production negatively correlates with HK-2 cell impairment: Evaluation of NGAL as a marker of toxicity in HK-2 cells. Toxicol In Vitro. 2017 Mar;39:52-57. doi: 10.1016/j.tiv.2016.11.012. Epub 2016 Nov 22.
• [64] Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
• [65] Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells. FASEB J. 2004 May;18(7):884-6. doi: 10.1096/fj.03-0687fje. Epub 2004 Mar 4.
• [66] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [67] Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5573-80. doi: 10.1128/AAC.00907-16. Print 2016 Sep.
• [68] Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
• [69] Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9.
• [70] Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis. Biochem J. 2002 Feb 1;361(Pt 3):635-9.
• [71] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [72] Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006 Nov 15;58(11):1136-63.
• [73] Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
• [74] Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006 May;91(1):140-9.
• [75] Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
• [76] Antimicrobial drugs used in the management of anaerobic infections in children. Drugs. 1983 Dec;26(6):520-9.
• [77] A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
• [78] Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
• [79] EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis. Antimicrob Agents Chemother. 2002 Oct;46(10):3223-7.
• [80] beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. Antimicrob Agents Chemother. 1999 May;43(5):1270-3.
• [81] Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents. Antimicrob Agents Chemother. 1999 Oct;43(10):2383-8.
• [82] Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
• [83] Genetic and biochemical characterization of CGB-1, an Ambler class B carbapenem-hydrolyzing beta-lactamase from Chryseobacterium gleum. Antimicrob Agents Chemother. 2002 Sep;46(9):2791-6.
• [84] Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices. J Pharmacol Exp Ther. 2007 Apr;321(1):362-9. doi: 10.1124/jpet.106.113076. Epub 2007 Jan 25.
• [85] Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):283-92.
• [86] An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens. Toxicol In Vitro. 2017 Apr;40:11-25. doi: 10.1016/j.tiv.2016.12.005. Epub 2016 Dec 10.
• [87] A plasmacytoid dendritic cell (CD123+/CD11c-) based assay system to predict contact allergenicity of chemicals. Toxicology. 2009 Oct 1;264(1-2):1-9. doi: 10.1016/j.tox.2009.07.021. Epub 2009 Aug 7.
• [88] NCTC 2544 and IL-18 production: a tool for the identification of contact allergens. Toxicol In Vitro. 2013 Apr;27(3):1127-34. doi: 10.1016/j.tiv.2012.05.018. Epub 2012 Oct 9.
• [89] Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.